Patient Innovation

Press enter to start searching

  • 1442
  • 1
  • 2
  • 0
  • Help Ukraine

Classmates develop binocular amblyopia therapy - Luminopia - to help in the Amblyopia Treatment

Shared by Joana Santos Afonso on 2023-04-02 22:50

About the solution

Luminopia is a startup company that was founded in 2017 by two Harvard University undergraduate students, Scott Xiao and Dean Travers. The company was established with the goal of developing treatments for visual and cognitive disorders, such as amblyopia or lazy eye, using virtual reality (VR) technology.

Their main product, LumiThera, is a VR-based therapy platform that provides customized therapy sessions to patients with visual and cognitive disorders. During the therapy sessions, the patient wears a VR headset and performs a series of visual tasks and exercises designed to stimulate and challenge their visual processing abilities. The VR environment is engaging and interactive, which helps to keep patients motivated and engaged during their therapy sessions.

The technology behind LumiThera is based on the principle of neuroplasticity, which refers to the brain's ability to reorganize and adapt in response to new stimuli. LumiThera aims to improve patients' visual processing abilities and overall visual function by providing them with stimulating and interactive visual experiences.

Luminopia's technology has undergone a rigorous development process, similar to that of a new pharmaceutical product. The technology has been evaluated in three clinical trials, with over 200 patients at more than 20 hospitals and research sites across the US. A randomized controlled Phase 3 trial, considered the gold standard, demonstrated the safety and efficacy of the therapy for children aged 4-7 years.

Unlike traditional amblyopia therapies, such as patching and atropine drops, which punish the stronger eye to force the brain to pay attention to the weaker eye, Luminopia aims to teach the eyes how to work together properly. The technology is built on decades of cutting-edge research conducted by leading clinicians and neuroscientists at Boston Children's Hospital and MIT.

Story adapted from: https://techcrunch.com/2021/10/01/how-four-person-startup-luminopia-is-u...

Learn more about this innovation at: https://luminopia.com/
And follow them at their socials: https://www.facebook.com/luminopia

https://www.youtube.com/watch?v=a0qehoMOa5E

This solution shall not include mention to the use of drugs, chemicals or biologicals (including food); invasive devices; offensive, commercial or inherently dangerous content. This solution was not medically validated. Proceed with caution! If you have any doubts, please consult with a health professional.

DISCLAIMER: This story was written by someone who is not the author of the solution, therefore please be advised that, although it was written with the utmost respect for the innovation and the innovator, there can be some incorrect statements. If you find any errors please contact the patient Innovation team via info@patient-innovation.com

About the author

The inspiration behind the founding of Luminopia came from the struggles of a fellow Harvard University classmate who had suffered from amblyopia as a child. The founders, Scott Xiao and Dean Travers, discovered that amblyopia affects about 3% of the population and can result in vision problems such as poor depth perception, double vision, and poor eye coordination. They were driven by a desire to help individuals with visual impairments and improve their quality of life. Through their innovative use of VR technology, Luminopia has the potential to make a real impact in the lives of those who

Tags associated to this solution

Like solution
Close en
Close

Welcome to Patient Innovation

Login with

Log in with Facebook

or

Forgot your password?

Not a member yet? Register now, it's free!